{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:02:18Z","timestamp":1780628538236,"version":"3.54.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Seizures are life-threatening complications of neuropsychiatric systemic lupus erythematosus (NPSLE) and are often associated with poor outcomes. Cyclophosphamide immunotherapy is the mainstay of NPSLE treatment. We report the unique case of a patient with NPSLE who developed seizures soon after her first and second doses of low-dose cyclophosphamide. The exact pathophysiological mechanism underlying cyclophosphamide-induced seizures is not well understood. However, this unusual drug-associated side effect of cyclophosphamide is thought to be due to the drug\u2019s unique pharmacology. Clinicians should be aware of this complication to make a correct diagnosis and adjust the immunosuppressive regimens very carefully.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1122629","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T22:50:57Z","timestamp":1678834257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cyclophosphamide-induced seizures in a patient with neuropsychiatric systemic lupus erythematosus (NPSLE): A case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Lingshu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","article-title":"The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semarthrit.2010.08.001","article-title":"Neuropsychiatric syndromes in systemic lupus erythematosus: A meta-analysis","volume":"41","author":"Unterman","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12916-015-0269-8","article-title":"Neuropsychiatric lupus: A mosaic of clinical presentations","volume":"13","author":"Kivity","year":"2015","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.106351","article-title":"Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus","volume":"69","author":"Hanly","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-13.2.62","article-title":"Epilepsy associated with systemic autoimmune disorders","volume":"13","author":"Devinsky","year":"2013","journal-title":"Epilepsy Curr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1349042","article-title":"Clinical features and outcomes of neuropsychiatric systemic lupus erythematosus in China","volume":"2021","author":"Zhang","year":"2021","journal-title":"J Immunol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: Golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.148","article-title":"Neuropsychiatric systemic lupus erythematosus: Pathogenesis and biomarkers","volume":"10","author":"Jeltsch-David","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102780","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus: A review","volume":"20","author":"Carrion-Barbera","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.40591","article-title":"Review: Nervous system disease in systemic lupus erythematosus: Current status and future directions","volume":"71","author":"Hanly","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317691373","article-title":"Magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus: Current state of the art and novel approaches","volume":"26","author":"Postal","year":"2017","journal-title":"Lupus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316674820","article-title":"Advanced MRI techniques: Biomarkers in neuropsychiatric lupus","volume":"26","author":"Sarbu","year":"2017","journal-title":"Lupus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000822","article-title":"Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus","volume":"33","author":"Mackay","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1191\/0961203303lu251oa","article-title":"Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)","volume":"12","author":"Stojanovich","year":"2003","journal-title":"Lupus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025528","article-title":"Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus","volume":"64","author":"Barile-Fabris","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semarthrit.2020.12.004","article-title":"Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review","volume":"51","author":"Papachristos","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/181931a0","article-title":"Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat","volume":"181","author":"Arnold","year":"1958","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: Implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"w14030","DOI":"10.4414\/smw.2014.14030","article-title":"Cyclophosphamide: As bad as its reputation? long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases","volume":"144","author":"Dan","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i21.6130","article-title":"Oral cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis: A case report","volume":"9","author":"Kim","year":"2021","journal-title":"World J Clin cases"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3173-1","article-title":"A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide","volume":"35","author":"Jabrane","year":"2015","journal-title":"Rheumatol Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.07.2008.0467","article-title":"Cyclophosphamide-induced reversible posterior leukoencephalopathy syndrome","volume":"2009","author":"Abenza-Abildua","year":"2009","journal-title":"BMJ Case Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5049\/EBP.2017.15.1.12","article-title":"Unusual case of posterior reversible encephalopathy syndrome in a patient with anti-glomerular basement membrane antibody glomerulonephritis: A case report and review of the literature","volume":"15","author":"Cha","year":"2017","journal-title":"Electrolyte Blood Press"},{"key":"B24","article-title":"Demystifying serotonin syndrome (or serotonin toxicity)","volume":"64","author":"Foong","year":"2018","journal-title":"Can Fam Phys"},{"key":"B25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12888-015-0701-9","article-title":"Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: Cohort study using a primary care database","volume":"15","author":"Hill","year":"2015","journal-title":"BMC Psychiatry"},{"key":"B26","first-page":"13","article-title":"Cyclophosphamide increases 5-hydroxytryptamine release from the isolated ileum of the rat","volume":"97","author":"Minami","year":"1997","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/1744806916674479","article-title":"Spinal astrocytic activation contributes to mechanical allodynia in a rat model of cyclophosphamide-induced cystitis","volume":"12","author":"Liu","year":"2016","journal-title":"Mol Pain"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000365832","article-title":"Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: Report of two cases","volume":"7","author":"Baker","year":"2014","journal-title":"Case Rep Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-248408","article-title":"Severe hyponatraemia in two patients with breast cancer caused by low-dose cyclophosphamide and precipitated by aprepitant","volume":"15","author":"Parikh","year":"2022","journal-title":"BMJ Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1122629\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T22:51:00Z","timestamp":1678834260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1122629\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2023.1122629"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1122629","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"article-number":"1122629"}}